Neurocrine Biosciences | NBIX - Crediti Commerciali





Crediti Commerciali Cambiamento Data
AbbVie USD 12.59B 180M 2025-12
Acadia Pharmaceuticals USD 148.38M 153K 2026-03
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
ALKERMES USD 407.63M 73.6M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amgen USD 9.14B 432M 2026-03
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Cytokinetics USD 6.83M 10.94M 2026-03
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Exelixis USD 328.95M 42.03M 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
Halozyme Therapeutics USD 457.99M 16.72M 2026-03
Incyte USD 1.05B 27.09M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Pfizer USD 16.17B 332M 2026-03
Prothena USD 5.16M 0 2023-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Repligen USD 151.55M 7.03M 2026-03
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Teva Pharmaceutical Industries USD 3.39B 316M 2026-03
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03
Xoma USD 14.78M 4.96M 2024-06